(Q35618783)

9 August 2017

1 reference

title

Part II: Hodgkin's lymphoma--diagnosis and treatment (English)

1 reference

9 August 2017

Volker Diehl

1

1 reference

9 August 2017

Roman K Thomas

series ordinal

2

1 reference

9 August 2017

Daniel Re

series ordinal

3

1 reference

9 August 2017

publication date

1 January 2004

1 reference

Lancet Oncology Commission

9 August 2017

published in

1 reference

9 August 2017

volume

5

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

19-26

1 reference

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

1 reference

7 January 2021

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Long-term follow-up of Hodgkin's disease trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Advanced Hodgkin's disease: ABVD is better, yet is not good enough!

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Treatment of relapsed Hodgkin's disease: strategies and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Autologous bone marrow transplantation for patients with relapsed hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901320-2

7 January 2021

10.1016/S1470-2045(03)01320-2

Identifiers

DOI

1 reference

9 August 2017

1 reference